In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
- PMID: 2039206
- PMCID: PMC245047
- DOI: 10.1128/AAC.35.3.542
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins
Abstract
Newly synthesized rifamycin derivatives, KRM-1648, KRM-1657, KRM-1668, KRM-1686, and KRM-1687, having the chemical structures of 3'-hydroxy-5'-(4-alkylpiperazinyl)-benzoxazinorifamycins (alkyl residues: isobutyl, propyl, sec-butyl, sec-butyl [R configuration], and sec-butyl [S configuration], respectively), were studied for their in vitro antimycobacterial activities. Representative (KRM-1648) MICs for 90% of the strains tested, determined by the agar dilution method on 7H11 medium, of various pathogenic mycobacteria (9 species, 174 strains) were as follows (in micrograms per milliliter): Mycobacterium tuberculosis (rifampin [RMP]-susceptible strains), less than or equal to 0.0125; M. tuberculosis (RMP-resistant strains), 12.5; M. kansasii, 0.05; M. marinum, less than or equal to 0.0125; M. scrofulaceum, 0.1; M. avium, 1.56; M. intracellulare, 0.1; M. fortuitum, greater than 100; and M. chelonae subsp. abscessus and M. chelonae subsp. chelonae, greater than 100. These values are more than 64 times lower than those of RMP, except for the values against RMP-resistant M. tuberculosis (8 times lower) and those against rapid growers, including M. fortuitum and M. chelonae (the same as those of RMP). The other derivatives had similar levels of in vitro activity against these mycobacteria. When murine peritoneal macrophages in which M. intracellulare was phagocytosed in vitro were cultured in the presence of the benzoxazinorifamycins (1 microgram/ml), much more rapid killing of the organisms ingested in the macrophages was seen compared with when the same amount of RMP was added to the medium. The addition of benzoxazinorifamycins at the concentration of 0.05 micrograms/ml caused more marked suppression of intracellular growth of the organisms compared with addition of RMP. KRM-1648 and KRM-1657 inhibited intracellular growth of M. tuberculosis, and their efficacies were much greater than that of RMP.
Similar articles
-
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.Antimicrob Agents Chemother. 2000 Feb;44(2):283-6. doi: 10.1128/AAC.44.2.283-286.2000. Antimicrob Agents Chemother. 2000. PMID: 10639351 Free PMC article.
-
In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.Antimicrob Agents Chemother. 1995 Oct;39(10):2295-303. doi: 10.1128/AAC.39.10.2295. Antimicrob Agents Chemother. 1995. PMID: 8619585 Free PMC article.
-
[Antimycobacterial activity of a newly synthesized fluoroquinolone, Y-26611].Kekkaku. 1992 Jul;67(7):515-20. Kekkaku. 1992. PMID: 1331603 Japanese.
-
[In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].Kekkaku. 1999 Jan;74(1):63-70. Kekkaku. 1999. PMID: 10067057 Review. Japanese.
-
Prospects for development of new antimycobacterial drugs.J Infect Chemother. 2000 Mar;6(1):8-20. doi: 10.1007/s101560050043. J Infect Chemother. 2000. PMID: 11810525 Review.
Cited by
-
Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.Antimicrob Agents Chemother. 1994 Oct;38(10):2245-8. doi: 10.1128/AAC.38.10.2245. Antimicrob Agents Chemother. 1994. PMID: 7840552 Free PMC article.
-
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.Antimicrob Agents Chemother. 1993 Jun;37(6):1259-63. doi: 10.1128/AAC.37.6.1259. Antimicrob Agents Chemother. 1993. PMID: 8392307 Free PMC article.
-
In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.Antimicrob Agents Chemother. 1996 Feb;40(2):426-8. doi: 10.1128/AAC.40.2.426. Antimicrob Agents Chemother. 1996. PMID: 8834891 Free PMC article.
-
Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.Antimicrob Agents Chemother. 1996 Feb;40(2):400-7. doi: 10.1128/AAC.40.2.400. Antimicrob Agents Chemother. 1996. PMID: 8834887 Free PMC article.
-
In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli.Antimicrob Agents Chemother. 1995 Feb;39(2):440-4. doi: 10.1128/AAC.39.2.440. Antimicrob Agents Chemother. 1995. PMID: 7726512 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources